GREAT SCIENCE. GREAT MEDICINE.
CREATING BREAKTHROUGH TREATMENTS.
HGS is working to create and develop novel therapies that can extend and improve the quality of life. That is our passion.
Products in Late-Stage Development
We have promising products in late-stage development – one already commercialized and another moving toward commercialization. BENLYSTA® (belimumab) has successfully completed Phase 3 development in systemic lupus. We and GlaxoSmithKline submitted marketing applications for BENLYSTA in the United States and Europe in June 2010.
In the first half of 2009, we achieved our first product sales by delivering 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for use in the event of an emergency to treat inhalation anthrax. In July 2009, we secured a new purchase order for 45,000 additional doses of raxibacumab to be delivered over a three-year period. We delivered approximately 5,600 doses under the new order in fourth quarter 2009, and expect to deliver approximately 15,000 doses to the Stockpile in 2010.
Emerging Mid-Stage Pipeline
Right behind these late-stage products is an emerging mid-stage pipeline, led by our oncology program and potential additional indications for BENLYSTA. We also have substantial financial rights to a number of products in the GlaxoSmithKline clinical pipeline. GSK is currently conducting Phase 3 clinical trials of darapladib in men and women with chronic coronary heart disease and Syncria® (albiglutide) in patients with type 2 diabetes mellitus.
We are committed to improving the lives of patients – and to achieving commercial success and sustainable growth well into the future.